Trial Profile
A Phase IV Post-Marketing Study Evaluating the Safety, Immunogenicity and Efficacy of the Marketed Formulation of Hetero - Bevacizumab in Solid Malignancies
Status:
Not yet recruiting
Phase of Trial:
Phase IV
Latest Information Update: 04 Jul 2019
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary)
- Indications Cervical cancer; Colorectal cancer; Glioblastoma; Non-small cell lung cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions
- Sponsors Hetero Drugs
- 25 Jun 2018 New trial record